Compare ETB & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | MASS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.8M | 498.1M |
| IPO Year | 2004 | 2020 |
| Metric | ETB | MASS |
|---|---|---|
| Price | $15.03 | $10.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 60.7K | ★ 353.1K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,197,000.00 |
| Revenue This Year | N/A | $22.78 |
| Revenue Next Year | N/A | $19.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.86 | $5.03 |
| 52 Week High | $15.82 | $13.35 |
| Indicator | ETB | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 45.40 |
| Support Level | $15.05 | $6.20 |
| Resistance Level | $15.64 | $10.88 |
| Average True Range (ATR) | 0.19 | 0.87 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 75.00 | 22.12 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.